Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
, 7 (21), 2352-7

Neurosurgical Procedures in Patients With Liver Cirrhosis: A Review

Affiliations
Review

Neurosurgical Procedures in Patients With Liver Cirrhosis: A Review

Ching-Chang Chen et al. World J Hepatol.

Abstract

Liver cirrhosis, a devastating liver fibrosis caused by hepatitis/inflammation or tumors, is a major comorbid factor in known surgery fields, such as cardiovascular and abdominal surgeries. It is important to review possible comorbid results in neurosurgical procedures in cirrhotic patients. In the reviewed literature, Child-Pugh and model for end-stage liver disease scores are commonly used in the assessment of surgical risks for cirrhotic patients undergoing abdominal, cardiovascular or neurosurgical procedures. The major categories of neurosurgery are traumatic brain injury (TBI), spontaneous intracranial hemorrhage (SICH), brain tumors, and spinal instrumentation procedures. TBI was reported with surgical mortality as high as 34.5% and a complication rate of 87.2%. For SICH, mortality ranged from 22.7% to 47.0%, while complications were reported to be 43.2%. Less is discussed in brain tumor patients; still the postoperative hemorrhage rate approached 26.7%. In spinal fusion instrumentation procedures, the complication rate was as high as 41.0%. Preoperative assessment and correction could possibly decrease complications such as hemorrhage, wound infection and other cirrhosis-related complications (renal, pulmonary, ascites and encephalopathy). In this study, we reviewed the neurosurgical-related literature with regard to liver cirrhosis as a prognostic factor influencing neurosurgical outcomes.

Keywords: Brain tumor; Complications; Liver cirrhosis; Neurosurgery; Spine surgery; Spontaneous intracranial hemorrhage; Surgical risks; Traumatic brain injury.

Figures

Figure 1
Figure 1
Preoperative assessment and management for patients planned receiving regular neurosurgical procedures. MELD: Model for end-stage liver disease.
Figure 2
Figure 2
Management for patients receiving emergent neurosurgical procedures.

Similar articles

See all similar articles
Feedback